Filtered By:
Specialty: Drugs & Pharmacology
Condition: Bleeding
This page shows you your search results in order of date. This is page number 13.
Order by Relevance | Date
Total 688 results found since Jan 2013.
Efficacy and safety of direct oral anticoagulants in the treatment of left ventricular thrombus after acute anterior myocardial infarction in patients who underwent percutaneous coronary intervention
CONCLUSIONS: DOACs appears to be a suitable alternative to warfarin for the management of LVT post STEMI, especially in patients who are intolerant to warfarin.PMID:36200193 | DOI:10.2174/1570161120666221003104821
Source: Current Vascular Pharmacology - October 6, 2022 Category: Drugs & Pharmacology Authors: Jing Liang Zhijian Wang Yujie Zhou Hua Shen Meng Chai Xiaoteng Ma Hongya Han Qiaoyu Shao Qiuxuan Li Source Type: research
Prevalence and risk of inappropriate dosing of direct oral anticoagulants in two Swiss atrial fibrillation registries
CONCLUSION: Inappropriate DOAC-dosing was more prevalent in multimorbid patients, but did not correlate with higher risks of adverse events after adjusting for confounders. DOAC prescription should follow label.PMID:36182083 | DOI:10.1016/j.vph.2022.107120
Source: Vascular Pharmacology - October 1, 2022 Category: Drugs & Pharmacology Authors: Giulia Montrasio Martin F Reiner Andrea Wiencierz Stefanie Aeschbacher Christine Baumgartner Nicolas Rodondi Michael K ühne Giorgio Moschovitis Helga Preiss Michael Coslovsky Maria L De Perna Leo H Bonati David Conen Stefan Osswald Juerg H Beer Pascal Ko Source Type: research
Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: A network meta-analysis of randomized controlled trials
Aimed to evaluate and compare the interactive effects of different antiplatelet or anticoagulation strategies in patients with chronic coronary syndromes (CCS) after percutaneous coronary intervention (PCI). Randomized controlled trials comparing different antiplatelet or anticoagulant strategies in patients with CCS after PCI were included. The primary outcomes were major adverse cardiovascular event (MACE), mortality, ischemic and bleeding events. Compared to aspirin alone, addition of prasugrel or ticagrelor to aspirin resulted in lower risk of myocardial infarction (MI) [odds ratio (OR): 0.38 (95% confidence interval 0...
Source: Frontiers in Pharmacology - September 30, 2022 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Anticoagulants in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: A Systematic Review and Multilevel Meta-Analysis
ConclusionNOACs were associated with less intracranial hemorrhages and ischemic strokes/systemic embolisms than VKAs in AF patients at risk of falls. These findings suggesting preferred use of NOACs over VKAs have clinical implications for physicians, patients and policy makers.
Source: Drug Safety - September 19, 2022 Category: Drugs & Pharmacology Source Type: research
Efficacy and safety of tranexamic acid for patients with intertrochanteric fractures treated with intramedullary fixation: A systematic review and meta-analysis of current evidence in randomized controlled trials
Conclusion: TXA is an effective and safe drug for perioperative bleeding control in intertrochanteric fracture patients treated with intramedullary fixation. However, the long-term efficacy of TXA still needs to be investigated by large-scale multicenter randomized controlled trials.Level of evidence: II, Systematic review and Meta-analysis.Systematic Review Registration:https://inplasy.com/, identifier [INPLASY202280027]
Source: Frontiers in Pharmacology - September 19, 2022 Category: Drugs & Pharmacology Source Type: research
The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study
ConclusionA significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.
Source: European Journal of Clinical Pharmacology - September 19, 2022 Category: Drugs & Pharmacology Source Type: research
Antiplatelet therapy after acute ischemic stroke or transient ischemic attack
Expert Rev Clin Pharmacol. 2022 Aug 27. doi: 10.1080/17512433.2022.2118713. Online ahead of print.ABSTRACTINTRODUCTION: Antiplatelet therapy is key to prevent recurrences in patients with an acute or prior non-cardioembolic stroke or transient ischemic attack (TIA). The narrow balance between the risks of ischemic recurrence and major bleeding is a relevant clinical dilemma.AREAS COVERED: This review covers the current evidence on antiplatelet therapy for patients with non-cardioembolic stroke or TIA. Randomized controlled trials of antithrombotic strategies of patients with these conditions were searched in Pubmed/Medline...
Source: Pharmacological Reviews - August 29, 2022 Category: Drugs & Pharmacology Authors: Lorenzo Scalia Dario Calderone Davide Capodanno Source Type: research
Major Bleeding Postadministration of Tenecteplase Versus Alteplase in Acute Ischemic Stroke
CONCLUSIONS AND RELEVANCE: Tenecteplase had similar rates of major bleeding versus alteplase and may be a reasonable alternative in the treatment of acute ischemic stroke.PMID:36004394 | DOI:10.1177/10600280221120211
Source: The Annals of Pharmacotherapy - August 25, 2022 Category: Drugs & Pharmacology Authors: Mary N Walton Leslie A Hamilton Sonia Salyer Brian F Wiseman Ann M Forster A Shaun Rowe Source Type: research
